Physician profile
Ajay Jain
NPI 1023067477
$432,479.53
in general payments reported to CMS, 2019-2025
28 companies · $86K in 2025
The $86K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $17K · 2021: $47K · 2022: $45K · 2023: $52K · 2024: $122K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $217K · Travel and Lodging: $18K · Food and Beverage: $9,558 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,600 · Honoraria: $4,780 · Consulting Fee: $3,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $216,669.86 |
| Travel and Lodging | $18,151.55 |
| Food and Beverage | $9,558.31 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,600.00 |
| Honoraria | $4,780.00 |
| Consulting Fee | $3,680.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $94,951.31 | 2019-2025 | |
| Abbvie INC. | $81,170.36 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $66,993.20 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $66,170.43 | 2019-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $35,219.42 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $23,097.14 | 2020-2024 | Ocaliva |
| Allergan, INC. | $16,479.23 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $14,231.77 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $11,800.67 | 2024-2025 | Zenpep |
| Medtronic, INC. | $4,059.90 | 2023-2024 | Gi Genius |
| Celgene Corporation | $3,646.65 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $2,770.53 | 2019-2023 | Entyvio |
| Dova Pharmaceuticals | $2,732.22 | 2019 | |
| Boston Scientific Corporation | $2,673.37 | 2019-2025 | Exalt Model D, Spyglass, Wallflex Duodenal |
| Redhill Biopharma INC. | $2,405.23 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $2,225.00 | 2021 | |
| Ardelyx, INC. | $1,000.00 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $153.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.70 | 2019-2020 | |
| Cook Medical LLC | $116.70 | 2019-2024 | Hemospray |
| Lilly USA, LLC | $94.50 | 2024 | Omvoh |
| Braintree Laboratories, INC. | $73.31 | 2021 | |
| Ambu INC. | $65.05 | 2021 | |
| Conmed Corporation | $56.87 | 2021 | |
| Ironwood Pharmaceuticals, INC | $54.22 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.98 | 2019-2020 | |
| Shire North American Group INC | $31.51 | 2019 | |
| Concordia Pharmaceuticals INC. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.